In a recent article from FAZ, Prof. Dr. Matthias Schaier from TolerogenixX GmbH and Prof. Dr. Alexandre Loupy from Cibiltech have been mentioned for their innovative contributions in the field of kidney transplantation.
Kidney transplants can save lives, however in more than 60% of cases the patients new kidney is rejected by the immune system. For this reason, the current medical answer is standard immunosuppression. This treatment must be performed throughout and has considerable disadvantages, such as increased infections and tumor risks, as well as high costs.
In the region, we have a great example of healthcare innovations to support this acute medical need. TolerogenixX, a company created for Prof. Dr. Schaier, Prof. Dr. Morath and Dr. Schmitt, aims to deliver an individualized (tailored) immunosuppression. Using the patented treatment of white blood cells, the TolerogenixX method achieves a tailored immunomodulation for the individual patient, that can overcome the standard immunosuppression procedure. The same method could be used also with autoimmune diseases to address specifically the underlying problem rather than untargeted weakening of their body's defenses.
Another innovation towards solving this problem is the iBox technology developed by the Paris Transplant Group. Based on 20 years of research and renowned scientific excellence they have developed the first universal predictive algorithm in transplantation. These pioneers in AI for medicine were eager to translate the technology to the market. In early 2019, Prof. Dr. Alexandre Loupy, Prof. Dr. Xavier Jouven and Stéphane Tholander brought together a team of world-class scientists and experienced entrepreneurs to launch Cibiltech. The core technology of Predigraft, the iBox algorithm, provides a prediction of kidney allograft survival, enabling clinicians to anticipate patient health outcomes, improving medical decisions through personalized treatments. The iBox technology is also a key tool for clinical research with the potential to reduce the duration of clinical trials.
Recently both key opinion leader in the field, Prof. Dr. Matthias Schaier from TolerogenixX GmbH and Prof. Dr. Alexandre Loupy and it‘s created startup (Cibiltech), have been mentioned in the FAZ for their innovative contributions in the field of kidney transplantation.
Through the EIT Health Bridgehead programme we have established a connection between TolerogenixX and Cibiltech with the broader aim to foster the innovation in our region, through international cooperation.
More about TolerogenixX
More about Cibiltech
More about EIT Health Bridgehead programme